incretin raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-04-24. Anything still debated is marked as such rather than presented as settled.
Acting as a triple agonist, the molecule binds the GLP-1, GIP, and glucagon receptors. GLP-1 activity slows gastric emptying and dampens appetite, while GIP signaling contributes to insulin sensitivity and fat metabolism. Glucagon receptor engagement raises energy expenditure and encourages fat breakdown, although it can also elevate blood glucose. Combining three pathways is intended to yield larger weight reduction than single or dual agonists, and researchers continue to examine how the balance among them shapes tolerability.
Clinical studies have reported notable reductions in body weight among participants. Early trials measured safety and explored several dose levels, and later studies tracked body-weight change over months of treatment. Investigators also monitor effects on glycemic markers, liver fat, and blood lipids. Because the compound is still in development, questions about long-term safety, cardiovascular outcomes, and durability after treatment ends remain open.
Retatrutide is an investigational synthetic peptide that acts as an agonist at three distinct G protein-coupled receptors. It combines activity at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor within a single molecule. This multi-receptor profile distinguishes it from earlier incretin-based compounds that engage one or two of these pathways. Researchers designed the molecule to test whether simultaneous activation produces greater metabolic effects than single or dual agonism alone.
The peptide backbone is chemically modified to resist rapid enzymatic breakdown in the body. A fatty acid side chain promotes binding to serum albumin, which slows renal clearance and supports an extended circulation time. These modifications allow less frequent administration than would be possible with an unmodified peptide. The precise contribution of glucagon receptor activation to the overall metabolic effect remains an area of active investigation, because glucagon raises glucose while also increasing energy expenditure.
| Property | Value | Notes |
|---|---|---|
| Molecular weight | Approximately 4,700 Da | Peptide of roughly forty amino acids |
| Receptor targets | GLP-1, GIP, glucagon | Triple agonist class |
| Research code | LY3437943 | Internal development designation |
| Compound class | Incretin mimetic peptide | Synthetic, not a biologic extract |
| Development status | Investigational | No general regulatory approval |
Retatrutide is an investigational peptide developed by a pharmaceutical company as a multi-receptor agonist for treating obesity and type 2 diabetes. The compound emerged from research into gut-hormone analogues that act on several receptors simultaneously rather than on a single target. Early preclinical work examined how combined activity at three distinct receptors might produce greater metabolic effects than single-receptor compounds. Published phase 2 results have described substantial reductions in body weight among participants, although the compound remains unapproved in most jurisdictions as of the mid-2020s.
Pharmacologically, retatrutide acts as a triple agonist at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor. Activation of the first two receptors is associated with improved insulin secretion and reduced appetite. The glucagon receptor component is thought to increase energy expenditure, a mechanism that distinguishes this molecule from dual-agonist compounds. Researchers continue to investigate how the three activities interact and whether the combined profile offers advantages that justify additional clinical testing.
Several questions about the compound remain unresolved. The durability of weight reduction after treatment stops, the frequency of gastrointestinal side effects, and the long-term cardiovascular profile are topics of ongoing study. Regulatory submissions and phase 3 trial outcomes have not been fully reported in the public literature. Because most available data come from controlled trials rather than general-population use, conclusions about effectiveness outside study settings are provisional. The distinction between established findings and open questions matters when interpreting early coverage of the drug.
开发进程从早期单次和多次给药研究推进至大规模后期试验。公开报告显示，参与者在体重和相关代谢指标上出现变化，但完整数据需经同行评审并接受独立复核。试验设计通常包括随机、双盲和对照设置，以区分药物效应与行为干预。监管提交和标签范围尚未确定；长期维持效果与心血管结局仍是开放问题。
与仅靶向单一受体的同类药物相比，瑞他鲁肽增加胰高血糖素受体成分，理论上可提高能量消耗并改变脂肪分布。临床中观察到的体重变化是否主要来自该额外机制，目前尚无定论。胃肠道反应是该类药物常见不良事件，试验中通过剂量递增和监测进行管理。停药后体重反弹、个体差异和长期耐受性仍需更多数据。
Retatrutide is a synthetic peptide developed as a single molecule that activates three distinct hormone receptors: GLP-1, GIP, and glucagon. The compound carries the internal designation LY3437943 and was engineered by modifying the backbone of glucose-dependent insulinotropic polypeptide. Its sequence incorporates non-natural amino acids and a fatty acid side chain that extends circulation time. The triple-agonist design aims to combine appetite suppression, improved insulin response, and increased energy expenditure in one agent. Published reports describe it as an investigational product rather than an approved medicine.
Each receptor contributes a different physiological effect. Activation of the GLP-1 receptor slows gastric emptying and reduces appetite signaling in the brain. GIP receptor activity influences insulin secretion and lipid handling, while glucagon receptor stimulation raises energy use and fat oxidation. Combining these pathways is intended to produce weight loss beyond what single- or dual-receptor agonists achieve. Researchers attribute the observed potency to simultaneous engagement of all three targets, though the exact contribution of each receptor to overall effect remains under investigation.
Clinical development has advanced through phase 2 trials in adults with obesity and type 2 diabetes. Reported phase 2 results described substantial average weight reduction over roughly forty-eight weeks of weekly dosing. A phase 3 program is ongoing to confirm efficacy and assess long-term safety. Because the compound has not received regulatory approval, it is not available as a prescription product. Public discussion of retatrutide often conflates trial findings with marketed status, an important distinction when interpreting coverage of the topic.
FS−SF → S=SF2 Decomposing to sulfur tetrafluoride and sulfur when heated to 180 °C: 2 S2F2 → SF4 + 3 S Hydrolysis: 2 S2F2 + 2 H2O → SO2 + 3 S + 4 HF Reacting with sulfuric acid at 80 °C: S2F2 + 3 H2SO4 → 5 SO2 + 2 HF + 2 H2O Reacting with sodium hydroxide: 2 S2F2 + 6 NaOH → Na2SO3 + 3 S + 4 NaF + 3 H2O Reacting with oxygen at high pressure, using nitrogen dioxide as a catalyst: 2 S2F2 + 5 O2 → SOF4 + 3 SO3
The compartmentalization afforded by the periplasmic space gives rise to several important functions. Aside from those previously mentioned, the periplasm also functions in protein transport and quality control, analogous to the endoplasmic reticulum in eukaryotes. Furthermore, the separation of the periplasm from the cytoplasm allows for the compartmentalization of enzymes that could be toxic in the cytoplasm. Some peptidoglycans and lipoproteins located in the periplasm provide a structural support system for the cell that aids in promoting the cell's ability to withstand turgor pressure. Notably, organelles such as the flagellum require the assembly of polymers within the periplasm for proper functioning. As the driveshaft of the flagellum spans the periplasmic space, its length is dictated by positioning of the outer membrane as induced by its contraction, which is mediated by periplasmic polymers. The periplasm also functions in cell signaling, such as in the case of the lipoprotein RcsF, which has a globular domain residing in the periplasm and acts as a stress sensor. When RcsF fails to interact with BamA, such as in the case of an enlarged periplasm, RcsF is not exported to the cell surface and are able to trigger the Rcs signaling cascade. Periplasm size, therefore, plays an important role in stress signaling.
== See also == Delta sleep-inducing peptide – NeuropeptidePages displaying short descriptions of redirect targetsPages displaying short descriptions with no spaces Electroencephalography – Electrophysiological method to record electrical activity of the brain K-complex – Waveform seen during stage 2 NREM sleep Sensorimotor rhythm – Oscillatory idle rhythm of synchronized electric brain activity slow-wave sleep – Period of sleep in humans and other animals Wolff–Parkinson–White syndrome – Abnormal heart rhythm due to faulty electrical connections in the heart
Sources: en.wikipedia.org
== Environmental cleanup == There have been many attempts to eliminate perchlorate contamination. Current remediation technologies for perchlorate have downsides of high costs and difficulty in operation. Thus, there have been interests in developing systems that would offer economic and green alternatives.
=== Other mammals === A number of other mammals also have a requirement for taurine. While the majority of dogs can synthesize taurine, case reports have described a singular American Cocker Spaniel, 19 Newfoundland dogs, and a family of Golden Retrievers suffering from taurine deficiency treatable with supplementation. Foxes on fur farms also appear to require dietary taurine. The rhesus, cebus and cynomolgus monkeys each require taurine at least in infancy. The giant anteater also requires taurine.
Heseltine bought his first Jaguar, second hand and cheap because of the rise in the price of petrol owing to the Suez Crisis, for £1,750 in December 1956, upgrading to newer and more expensive models in future years. New Court Hotel was sold in 1957. At this point Heseltine went into business with another Oxford friend, Clive Labovitch, who brought out Opportunities for Graduates that year. Heseltine arranged for this to be distributed free, expanded from 40 pages to a 169-page hardback book, to final year students at all British universities, paid for by advertising. Heseltine ended his partnership with Josephs and with the aid of a £4,500 investment by Heseltine's mother (following the death of his father in 1957) he and Labovitch were able to buy a group of houses at 29–31 Tregunter Road (south of Earl's Court), adding two more in neighbouring Cathcart Road.
Sources: en.wikipedia.org
== Clinical significance == NNMT is highly expressed in the human liver. N-methylation is one method by which drug and other xenobiotic compounds are metabolized by the liver. NNMT expression in adipose tissue is associated with obesity and insulin resistance. Contrary to the negative effects of increased NNMT in adipose tissue, increased NNMT in liver is associated with a better metabolic profile, namely reduced serum triglycerides and free fatty acids. In adipose tissue, NNMT can lead to methylation depletion, whereas because of the many methylation enzymes in the liver NNMT has a negligible effect on liver methylation. But in the liver, the 1-methylnicotinamide produced by NNMT degradation of nicotinamide increases sirtuin 1 (SIRT1) by inhibiting degradation of that protein. Overexpression of SIRT1 in mice has been shown to reduce insulin and fasting glucose, as well as increased metabolism and physical function. Abundant availability of nicotinamide leads to depletion of both nicotinamide adenine dinucleotide (NAD+) and SAM-e, resulting in liver steatosis and fibrosis, causing the progression from non-alcoholic fatty liver disease (NAFLD) to non-alcoholic steatohepatitis (NASH). Human embryonic stem cells expression of NNMT is believed to help maintain the cells in a naive state. NNMT expression is significantly upregulated in many cancers, including pancreatic cancer where levels of NNMT enzyme correlate with increased risk of death. The cause of these correlations has not been established, but may be related to the fact that NNMT enzyme is an inhibitor of DNA repair.
In a short period of time, the seventeen-year-old went from open-mic nights at the club to regular paid shows, building his reputation in the process. Parallel to his increasing local Toronto-area popularity as an impressionist stand-up comic, Carrey tried to break into sketch comedy, auditioning to be a cast member for the 1980–81 season of NBC's Saturday Night Live. Carrey ended up not being selected by the show's new executive producer Jean Doumanian who picked thirty-one-year-old Charles Rocket instead. Decades later, after establishing himself as a Hollywood film star, Carrey would host the show in May 1996, January 2011, and October 2014. After not getting Saturday Night Live, Carrey took a voice acting job performing Clutch Cargo-inspired bits on The All-Night Show, an overnight program airing locally on the CFMT-TV channel branded as Multilingual Television (MTV). Continuing to perform his stand-up act of contortionist impressions in the city of Toronto and surrounding towns, in February 1981, nineteen-year-old Carrey was booked as the opening act for the rock band Goddo at The Roxy Theatre in Barrie for two shows on consecutive nights; the rock crowd booed him offstage and he refused to return for the second night. Two weeks later, however, a review of one of Carrey's spots at Yuk Yuk's—alongside a sizable photo of him doing a stage impression of Sammy Davis Jr.—appeared in the Toronto Star on the front page of its entertainment section with the writer Bruce Blackadar raving about "a genuine star coming to life".
Glutaredoxin 2 (GLRX2) is an enzyme that in humans, is encoded by the GLRX2 gene. GLRX2, also known as GRX2, is a glutaredoxin family protein and a thiol-disulfide oxidoreductase that maintains cellular thiol homeostasis. This gene consists of four exons and three introns, spanned 10 kilobase pairs, and localized to chromosome 1q31.2–31.3. Alternative splicing of GLRX2 leads to three isoforms of Grx2. One isoform, Grx2a, localizes to the mitochondria, is ubiquitously expressed in tissues (e.g. heart, skeletal muscle, kidney, and liver), regulates mitochondrial redox homeostasis, and protects cells against oxidative stress. Isoforms Grx2b and Grx2c, both localized to the nucleus and cytosol, are expressed only in testes and cancer cell lines and facilitate cellular differentiation and transformation, potentially inducing tumor progression.
Mike Evans tied the record for consecutive seasons with at least 1,000 receiving yards, with 11. He shares this record with Jerry Rice. Evans also extended his own record of most such seasons to start his career. Aaron Rodgers became the fifth player to have 500 passing touchdowns. Trey McBride set the record for most receptions by a tight end in his first three seasons, with 221. The previous record of 216 was held by George Kittle. The Buffalo Bills became the first team to score at least 30 rushing touchdowns and at least 30 passing touchdowns in a season. Wild Card Round
Sources: en.wikipedia.org
It is a synthetic peptide classified as a triple receptor agonist. It engages the GLP-1, GIP, and glucagon receptors at once. It is investigated for metabolic and weight-related conditions rather than approved for general use.
No regulatory agency has approved it for routine medical use. It remains an investigational compound studied in controlled trials. Access outside research settings is not established.
Each receptor influences energy balance through different pathways. Combining them is intended to add fat loss from lowered intake and higher expenditure. The optimal balance among the three effects is still under study.
Retatrutide is an investigational synthetic peptide that activates three metabolic receptors: GLP-1, GIP, and glucagon. It is being studied for obesity and type 2 diabetes. It has not been approved for clinical use.